Moderna Shares Fall After Reports of HHS Review of Bird Flu Vaccine Contract
Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the contract from the U.
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback